MyoKardia announced the successful completion of a $46 million Series B financing.
Proceeds from the financing will be used to advance and expand the company’s portfolio of potential therapies for hypertrophic and dilated cardiomyopathies (HCM and DCM), including its lead drug candidate, MYK-461, which is currently in Phase 1 clinical trials.
|Searching for more deal information? Current Partnering offers the following options:
The Series B financing included investments from an undisclosed public investment fund, Casdin Capital, Cormorant Asset Management, Perceptive Life Sciences, an affiliate of Cowen Group, and BridgeBio LLC.
Existing investor Sanofi also participated in the financing.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies